Themis Medicare's Q4 FY 2025-26 Quarterly Results

Result Summary

• Themis Medicare Ltd reported a 12.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.5%.
• Its expenses for the quarter were down by 8.9% QoQ and 5.3% YoY.
• The net profit decreased 11.9% QoQ and decreased 192.0% YoY.
• The earnings per share (EPS) of Themis Medicare Ltd stood at 0.96 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Themis Medicare Ltd is a pharmaceutical company that operates primarily in the manufacturing of drugs and related healthcare products. The company is involved in the development, manufacture, and marketing of a wide range of pharmaceutical formulations. Themis Medicare has established a reputation for its focus on niche products, which often include innovative therapies and treatments. The company is part of the pharmaceutical industry, which is characterized by research-intensive operations and a strong focus on compliance with regulatory standards. Information on recent major developments for Themis Medicare Ltd is not available within the provided data.

Revenue

In the fourth quarter of the fiscal year 2026, Themis Medicare Ltd reported a total income of ₹80.20 crores. This represents a quarter-over-quarter decrease of 12.3% from ₹91.42 crores in Q3FY26. However, there was a 9.5% year-over-year increase compared to ₹73.25 crores in Q4FY25. These figures indicate the company's revenue performance over the respective periods. The revenue trends highlight changes in sales and income generation capabilities within the timeframe provided.

Profitability

The company's profitability metrics for Q4FY26 include a Profit Before Tax (PBT) of ₹2.13 crores and a Profit After Tax (PAT) of ₹8.89 crores. The PBT experienced a significant quarter-over-quarter decrease of 56.3% from ₹4.87 crores in Q3FY26. Compared to Q4FY25, which recorded a negative PBT of ₹-9.21 crores, there was a marked improvement on a year-over-year basis. For the PAT, there was a quarter-over-quarter decline of 11.9% from ₹10.09 crores in Q3FY26, yet a substantial improvement from a negative PAT of ₹-9.66 crores in Q4FY25, marking a year-over-year growth of 192.0%.

Operating Metrics

Operating expenses for Themis Medicare Ltd in Q4FY26 were ₹78.07 crores, reflecting an 8.9% decrease from ₹85.68 crores in Q3FY26 and a 5.3% decrease from ₹82.47 crores in Q4FY25. The company's Earnings Per Share (EPS) for this quarter stood at ₹0.96, down from ₹1.09 in the previous quarter, indicating an 11.9% decline. However, this figure shows a significant recovery from the negative EPS of ₹-1.05 reported in Q4FY25, demonstrating a year-over-year growth of 191.4%. The various operating metrics provide insights into the company's operational efficiency and shareholder value generation over the analyzed periods.